TM 38837

Drug Profile

TM 38837

Alternative Names: TM38837

Latest Information Update: 23 Jul 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator 7TM Pharma
  • Class Obesity therapies; Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 19 Apr 2013 Pharmacokinetics data from a phase I trial in healthy volunteers released by 7TM Pharma
  • 20 Jan 2010 7TM Pharma is seeking a partnership for the accelerated clinical development of TM 38837 (
  • 20 Jan 2010 7TM Pharma conducts and completes a phase-I clinical trial in Obesity in Denmark (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top